Retension Pharmaceuticals
PrivateLast Round
Series B
Aug 6, 2025
Total Funding Raised
$25.4M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Retension Pharmaceuticals operates in Healthcare & Life Sciences and is based in Falls Church, Virginia. Its latest recorded funding round was a Series B round in August 2025.
Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for the treatment of hypertension and other serious cardiovascular conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Retension Pharmaceuticals Comparables
Compare Retension Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| E-Star BioTech, LLC | 81% | |
| Mineralys Therapeutics | 78% | |
| Alnylam Pharmaceuticals | 71% |
For institutional investors. Book with your work email.
Retension Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 6, 2025 | ||||
| Series A | Aug 21, 2024 |
For institutional investors. Book with your work email.
Retension Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dais Partners | Series B |
| Collage Venture Partners | Series A, Series B |
| Transhuman Capital | Series B |
| Green Park & Golf Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 5, 2026
Management to participate in fireside chat at Guggenheim Healthcare Innovation Conference.
- Aug 6, 2025
Raised $15M from Collage Venture Partners, Green Park & Golf Ventures, and others.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 10, 2026
Retension Pharmaceuticals, Inc. is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor for uncontrolled and resistant hypertension that enhances nitric oxide signaling in central arteries, with its Phase 2b trial ongoing under an exclusive worldwide license from Sanofi S.A.
- attends_eventNov 5, 2026
Management at Retension Pharmaceuticals, Inc. is scheduled to participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Massachusetts on Nov 10th '26.
- receives_financingOct 9, 2026
In Oct '26, Retension Pharmaceuticals, Inc. secures an upsized IPO offering due to generate $45 million in gross proceeds, compared with the $33.8M in net proceeds it suggests, with an additional $6.8 million possible if underwriters exercise their option.
- receives_financingOct 9, 2026
Retension Pharmaceuticals, Inc. announces pricing of an upsized $45M initial public offering on Oct 14th '26, with proceeds supporting its Phase 2b RTN-001 trial and planned Phase 3 trial; Leerink Partners, Guggenheim Securities and Oppenheimer & Co. serve as joint bookrunning managers, while Titan Partners serves as lead manager.
- is_developingOct 8, 2026
Retension Pharmaceuticals, Inc. is developing RTN-001 to enhance nitric oxide signaling in central arteries and address a core driver of hypertension; the Phase 2b trial is ongoing under an exclusive worldwide license from Sanofi.
For institutional investors. Book with your work email.
Retension Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Retension Pharmaceuticals's valuation, stock price, and market status.
Is Retension Pharmaceuticals a public or private company?
Retension Pharmaceuticals is a private company.
What is the current stock price of Retension Pharmaceuticals?
Retension Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Retension Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Retension Pharmaceuticals worth (valuation)?
Valuation information for Retension Pharmaceuticals is not publicly available.
Can I buy Retension Pharmaceuticals stock?
Retension Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Retension Pharmaceuticals's last funding round?
Retension Pharmaceuticals's most recent funding round was Series B on August 6, 2025.
Who are the main investors in Retension Pharmaceuticals?
Key investors in Retension Pharmaceuticals include Dais Partners, Collage Venture Partners, Transhuman Capital, Green Park & Golf Ventures.
Will Retension Pharmaceuticals IPO soon?
No public IPO plans have been announced for Retension Pharmaceuticals.
How can I track Retension Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Retension Pharmaceuticals's shares on secondary markets.